Latest Articles & Resources FEATURED SK pharmteco Announces $200M+ U.S. Investment in Small Molecules and Peptides Read More » SK pharmteco Announces $200M+ U.S. Investment in Small Molecules and Peptides Read More » LATEST NEWS + INTERVIEWS How to Select and Sustain an Early-Stage CDMO Partnership 53Biologics Announces €2M+ Investment in New Lyophilization Capacity TAPI Appoints Serge Rogasik as Chief Executive Officer ALK Expands Catalent Partnership to Secure Long-Term Allergy Tablet Supply OnDosis and Adare Pharma Solutions Launch U.S. ADHD Drug-Device Collaboration Ensera Launches Alliance Network for Drug-Device Combination Products Emerald Clinical Trials Appoints Former Novotech COO Michael Stibilj as CEO to Lead Next Phase of Asia-Pacific CRO Growth Merck Opens €70M Expansion at St. Louis ADC Manufacturing Center NorthStar Medical Technologies Secures Up to $185M Growth Capital Facility Piramal Pharma Solutions Receives $1.75M Ontario Investment for Aurora Site Minaris Adds Viral Vectors Business Unit to Expand CGT Model Genezen Partners on AAV9 Gene Therapy for Ultra-Rare ARCA2 Disorder ESTEVE CDMO Expands Morton Grove Facility With $33M Total Investment Forge Biologics Partners With TECPR2 Research Foundation on AAV Gene Therapy Axplora Completes First R&D Batches of Exatecan for ADC Developers Serán Bioscience Announces Growth Investment to Expand Commercial Manufacturing BioToxTech Targets 200% Growth in U.S. and European Non-Clinical CRO Orders With Bundled Turnkey Package Model Quotient Sciences and Acesion Pharma Launch AI Formulation Collaboration CARBOGEN AMCIS Completes First FDA Pre-Approval Inspection at Vionnaz Biodextris Appoints Clement Fourny as Chief Executive Officer Lifecore Biomedical Agrees to $663.7M Acquisition by Webster Equity Partners PODCAST INTERVIEWS How to Select and Sustain an Early-Stage CDMO Partnership What Changes When Pharma Outsources Outcomes, Not Just People? “Europe Needs to Pick a Side”: Why Geopolitics Is Forcing a Rethink of Pharma Supply Network Design
Emerald Clinical Trials Appoints Former Novotech COO Michael Stibilj as CEO to Lead Next Phase of Asia-Pacific CRO Growth
BioToxTech Targets 200% Growth in U.S. and European Non-Clinical CRO Orders With Bundled Turnkey Package Model
